CytoMed Therapeutics Ltd

GDTC

Company Profile

  • Business description

    CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.

  • Contact

    1 Commonwealth Lane
    No. 08-22 One Commonwealth
    Singapore149544
    SGP

    T: +65 62507738

    https://w2.cytomed.sg

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    42

Stocks News & Analysis

stocks

SpaceX is scaling AI infrastructure on earth, data centers in space might be next

Our view on the first results as a publicly traded company.
stocks

Investors too optimistic about overvalued ASX share

Upgraded first-half revenue guidance at the upper end of the previously announced range.
stocks

Restructuring at big four bank

Job cuts create capacity to invest as revenue growth slows.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,917.1039.50-0.44%
CAC 407,811.26110.42-1.39%
DAX 4025,371.75273.29-1.07%
Dow JONES (US)52,863.937.840.01%
FTSE 10010,725.0327.85-0.26%
HKSE22,934.68717.19-3.03%
NASDAQ26,166.59536.27-2.01%
Nikkei 22562,907.841,713.40-2.65%
NZX 50 Index13,746.8414.45-0.11%
S&P 5007,677.5079.67-1.03%
S&P/ASX 2008,793.2038.10-0.43%
SSE Composite Index3,658.0355.00-1.48%

Market Movers